Latest Pre-exposure prophylaxis Stories

AVAC Lays out Priorities to Ensure Access NEW YORK, July 11, 2012 /PRNewswire-USNewswire/ -- Publication of data from three trials of pre-exposure prophylaxis (PrEP) for HIV - including the pivotal Partners PrEP trial - today in the New England Journal of Medicine provides strong evidence that HIV-negative men and women who consistently take a daily antiretroviral (ARV) pill (either TDF/FTC, brand name Truvada, or TDF, brand name Viread) can significantly reduce their risk of HIV...

RESEARCH TRIANGLE PARK, N.C., July 11, 2012 /PRNewswire-USNewswire/ -- Results of the FHI 360 FEM-PrEP HIV-prevention trial reinforce the key role of adherence in HIV-prevention studies and the need to determine better approaches to support adherence in future pre-exposure prophylaxis (PrEP) programs. Despite targeted counseling and support, adherence to the drug regimen was low, suggesting that women in the clinical trial population may have had difficulty adhering to a daily pill...

(Ivanhoe Newswire) -- A new study shows that pre-exposure preventative treatment for suspected HIV may be effective for those in high-risk groups. "Although post-exposure prophylaxis has a long history of success, newer methods such as pre-exposure prophylaxis and earlier treatment in the course of infection ("treatment as prevention") are being implemented with some success," Dr. Isaac Bogoch, Harvard Medical School and the Division of Infectious Diseases, Massachusetts General Hospital,...

While immediate postexposure treatment for suspected HIV is critical, pre-exposure preventive treatment is a newer method that may be effective for people in high-risk groups, states a review of evidence published in CMAJ (Canadian Medical Association Journal). "Although postexposure prophylaxis has a long history of success, newer methods such as pre-exposure prophylaxis and earlier treatment in the course of infection ("treatment as prevention") are being implemented with some success,"...

"The FDA Decision to approve Truvada* by 19 votes against 3 in the prevention of HIV transmission on May 11 is irresponsible and against Global Public Health Interests," declares Doctor Alain Lafeuillade, Head of the Department of Infectious Diseases in Toulon (France) and Chair of the ISHEID to be held in Marseilles (France) in 6 days. Marseilles, France (PRWEB) May 17, 2012 The recent Truvada* FDA approval for pre-exposure prophylaxis "looks like a non sense in other...

WASHINGTON, May 17, 2012 /PRNewswire/ -- MS -- This summer, more than 25,000 leading scientists, public health experts, policy-makers, community members, and experts in the HIV/AIDS field from around the world will gather in our nation's capital for the International AIDS Society's XIX International AIDS Conference. This gathering provides a vital platform to address the global response to HIV/AIDS and the efforts to overcome barriers that limit access to care, services, prevention...

Pre-birth exposure to the anti-HIV drug tenofovir does not adversely affect pregnancy outcomes and does not increase birth defects, growth abnormalities, or kidney problems in infants born to African women who are HIV positive, supporting the use of this drug during pregnancy, according to a study by a team of international researchers published in this week's PLoS Medicine. The researchers led by Diana Gibb from the MRC Clinical Trials Unit in London, UK, analyzed data collected on...

Truvada alone not sufficient, given adherence and other challenges A drug that has been shown to prevent HIV infection in a significant number of cases must be combined with behavioral approaches if the U.S. health care establishment is to succeed in reducing the spread of the virus, according to the American Psychological Association. "Exclusive reliance on a drug to prevent HIV or any sexually transmitted disease could actually result in a worse outcome if those at risk don't...

NEW YORK, May 10, 2012 /PRNewswire-USNewswire/ -- AVAC hails the recommendation by an FDA Advisory Committee that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women. Citing the urgent need for new HIV prevention options to stem HIV infections, AVAC urges the FDA to issue an approval for all men and women at risk, and is calling on public health agencies, governments,...

Written Comments to FDA Advisory Committee Cite Compelling Evidence for PrEP and Urgent Need for Every Available Tool to End AIDS NEW YORK, May 1, 2012 /PRNewswire-USNewswire/ -- In public comments submitted this week, a group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of emtricitabine/ tenofovir disoproxil fumarate (TDF/FTC or Truvada®) as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult...